TLR7/8 agonist Resiquimod demonstrated significant tumor suppression in a metastatic model of lung adenocarcinoma, and a high-capacity poly (2-oxazoline) formulation of Resiquimod prolonged survival and mobilized anti-tumor CD8+ immunoreactivity in a chemotherapy-insensitive model of metastatic lung adenocarcinoma (Vinod et al., 2020). Here, CD8A is linked to neoplasm.